Es Tshd Treatment Approach

---
name: es-tshd-treatment-approach
description: This skill determines the appropriate treatment approach for thyroid-stimulating hormone deficiency (TSHD) in childhood cancer survivors. It recommends using the same levothyroxine dosing and monitoring strategies (e.g., target free T4 levels) as in the noncancer population, triggered by questions such as "How should I treat central hypothyroidism in this survivor?" or "What levothyroxine dose is appropriate for TSHD?"
---

# Select TSHD treatment strategy

## STEP 1 — Gather Information
Collect history of hypothalamic-pituitary radiation ≥30 Gy, tumors/surgery involving HP region, other pituitary deficits, symptoms of central hypothyroidism, baseline free T4 and TSH, and assess adrenal axis function.

## STEP 2 — Rule In / Rule Out
Rule in TSHD if free T4 is low or low-normal with normal or mildly elevated TSH (not elevated as in primary hypothyroidism); rule out primary hypothyroidism (high TSH) and non-thyroidal illness.

## STEP 3 — Classify or Stratify
Classify based on free T4 level (low vs low-normal) and confirm adrenal sufficiency before thyroid hormone replacement.

## STEP 4 — Decide
Initiate levothyroxine replacement using weight-based dosing (e.g., 1.6 µg/kg/day) as in noncancer population; aim for free T4 in middle to upper half of normal range; recheck free T4 4–6 weeks after dose change or starting GH; monitor annually; do not use TSH for monitoring adequacy.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on TSH to assess thyroid hormone adequacy in TSHD; ensure adrenal axis is adequate before starting levothyroxine to prevent adrenal crisis; be aware of enzyme‑inducing antiepileptics (e.g., phenytoin, carbamazepine) that may increase levothyroxine metabolism; avoid using TSH surge analysis or TRH stimulation for diagnosis.

## Concrete Clinical Example
A 16‑year‑old survivor treated with craniospinal irradiation 35 Gy presents with fatigue, free T4 at low‑normal limit, TSH normal, and normal adrenal function. Start levothyroxine 1.6 µg/kg/day, target free T4 mid‑normal, recheck in 6 weeks.

**Source:** Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-01175